Displacing an entrenched blockbuster drug requires defeating it in a direct, head-to-head trial.
To bypass competitor advantages and secure market dominance, drug developers are increasingly running Phase 3 trials designed to clinically demonstrate clear superiority directly against established treatment standards.
The same conclusion keeps arriving from across the workspace's research — 1 topics independently instantiate this theme. Filter the evidence by where it came from:
Takeda positioned zasocitinib to displace Sotyktu by validating its clinical superiority in a rigorous head-to-head Phase 3 plaque psoriasis trial.
To establish a dominant market presence for its new oral GLP-1, Eli Lilly launched a head-to-head Phase 3 trial directly proving superior weight loss over oral semaglutide.
Developers of this novel bispecific antibody proved its commercial potential by directly challenging and defeating the current clinical standard of care in a head-to-head trial.
Sanofi is using the newly approved subcutaneous hands-free delivery system of Sarclisa to challenge and displace J&J's dominant blockbuster competitor in the myeloma market.
The finding presents a new drug seeking market dominance by launching directly head-to-head against an entrenched competitor with a broader label spanning multiple disease settings.